Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G

Slides:



Advertisements
Similar presentations
Oxidative stress and hypoxia in normal and leukemic stem cells Ugo Testa, Catherine Labbaye, Germana Castelli, Elvira Pelosi Experimental Hematology Volume.
Advertisements

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.
Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.
Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination  Bipin.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
by Michael F. Leahy, and J. Harvey Turner
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience  Jean El-Cheikh, Roberto.
Kinetics and symmetry of divisions of hematopoietic stem cells
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy- Refractory Non-Hodgkin Lymphoma  Robert M. Dean, Daniel H. Fowler,
Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.
Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.
Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation  Bipin N. Savani, Theresa Donohue,
Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma  Robert Chen, Joycelynne.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure  César O. Freytes, Mei-Jie Zhang,
Christopher E. Schmitt, Carlos O. Lizama, Ann C. Zovein 
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
Autologous Stem Cell Transplant in Patients with Primary Central Nervous System Lymphoma: A Multicenter Analysis From the Sarah Cannon Blood Cancer Network 
Classic and Overlap Chronic Graft-versus-Host Disease (cGVHD) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP)  Madan H. Jagasia,
Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert.
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Geographic Distance Is Not Associated with Inferior Outcome When Using Long-Term Transplant Clinic Strategy  Brittany Knick Ragon, Carey Clifton, Heidi.
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma  Anuj Mahindra, Brian Bolwell, Ronald.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma  Stephen.
Inside This Issue Experimental Hematology
Sustained Suppression of Involved Free Light Chain Predicts Long Term Outcomes in Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation:
Sietske T. Bakker, Emmanuelle Passegué  Experimental Hematology 
Tumor necrosis factor α in the onset and progression of leukemia
Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome  Scott R. Solomon, Bipin N. Savani, Richard.
Kinase signaling and targeted therapy for primary myelofibrosis
Biology of Blood and Marrow Transplantation
Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R
Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma  Tanya M. Wildes, Kristan M. Augustin, Diane.
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria  Madan Jagasia, Jennifer Giglia, Wichai.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation 
Stem cell biology and the plasticity polemic
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion  Franck E. Nicolini, Eric Wattel, Anne-Sophie.
High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia 
Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗  Theresa Hahn, Philip L. McCarthy,
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis 
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell.
Pediatric leukemia: Moving toward more accurate models
by Lapo Alinari, and Kristie A. Blum
Autologous Stem Cell Transplantation for POEMS Syndrome
Presentation transcript:

Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma  Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G. Engelhardt, Madan H. Jagasia, Bipin N. Savani  Experimental Hematology  Volume 42, Issue 1, Pages 39-45 (January 2014) DOI: 10.1016/j.exphem.2013.09.012 Copyright © 2014 ISEH - Society for Hematology and Stem Cells Terms and Conditions

Figure 1 (A) Overall survival. (B) Progression-free survival. Experimental Hematology 2014 42, 39-45DOI: (10.1016/j.exphem.2013.09.012) Copyright © 2014 ISEH - Society for Hematology and Stem Cells Terms and Conditions

Figure 2 (A) Histology and survival after SCT. (B) Histology and PFS after SCT. Experimental Hematology 2014 42, 39-45DOI: (10.1016/j.exphem.2013.09.012) Copyright © 2014 ISEH - Society for Hematology and Stem Cells Terms and Conditions

Figure 3 (A) Disease status before SCT and survival. (B) Disease status before SCT and PFS. Experimental Hematology 2014 42, 39-45DOI: (10.1016/j.exphem.2013.09.012) Copyright © 2014 ISEH - Society for Hematology and Stem Cells Terms and Conditions

Figure 4 (A) Number of regimens for SCT and survival. (B) Number regimens before SCT and PFS. Experimental Hematology 2014 42, 39-45DOI: (10.1016/j.exphem.2013.09.012) Copyright © 2014 ISEH - Society for Hematology and Stem Cells Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.